Benefits
Estrogen Metabolism Modulation
trial showed I3C 400 mg/day shifted estrogen metabolism toward favorable 2-hydroxyestrone:16-alpha-hydroxyestrone ratio. Foundational mechanism — same effect as DIM.
Recurrent Respiratory Papillomatosis (RRP) Adjunct
trial showed I3C reduced papilloma recurrence in patients with juvenile/adult RRP. Mechanism: anti-HPV effects, immune modulation. Modest clinical evidence; adjunct only.
Cervical Dysplasia Adjunct
trial showed I3C reduced CIN 2/3 progression vs placebo. Similar mechanism to DIM. Adjunct only — standard screening/treatment foundational.
Phase I & II Detoxification Support
Induces both Phase I (CYP enzymes) and Phase II (sulfation, glucuronidation, glutathione conjugation) detoxification — supports clearance of estrogens, environmental toxins, drugs.
Antioxidant / Anti-Inflammatory
Modest direct antioxidant activity plus support of endogenous antioxidant systems. Anti-inflammatory effects via NF-κB modulation.
Mechanism of action
Conversion to DIM and Other Active Metabolites
I3C itself is largely converted in the acidic stomach environment to DIM (3,3'-diindolylmethane), ascorbigen, and indolo[3,2-b]carbazole (ICZ). I3C is essentially a 'pro-drug' for these active metabolites — DIM is the most studied.
CYP1A1/CYP1A2 Induction (Same as DIM)
Promotes estrogen 2-hydroxylation pathway. Same fundamental mechanism as DIM since I3C converts to DIM.
Aryl Hydrocarbon Receptor (AhR) Activation
ICZ (indolocarbazole) — an I3C metabolite — is one of the most potent natural AhR ligands. Activates extensive xenobiotic metabolism gene expression.
Anti-HPV Effects
Antiviral activity against HPV in cell culture. Mechanism for cervical dysplasia and RRP applications.
Clinical trials
Trial of I3C (400 mg/day) in healthy women for 2 months measuring urinary estrogen metabolites.
Healthy women.
Significantly increased 2-OH:16-alpha-OH estrogen metabolite ratio. Established I3C effects on estrogen metabolism.
Trial of I3C (400 mg/day) in patients with recurrent respiratory papillomatosis.
RRP patients.
Reduced recurrence rate in some patients. Generated interest in I3C as RRP adjunct. Limited subsequent confirmatory research.